Prelude Therapeutics Reports 2025 Results and Pipeline Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy PRLD?
Source: NASDAQ.COM
- Improved Financial Performance: Prelude Therapeutics reported a net loss of $99.5 million for 2025, translating to a loss of $1.29 per share, which is an improvement from the $127.2 million loss and $1.68 per share in 2024, primarily driven by reduced research and development expenses, indicating effective cost management.
- Strong Cash Position: The company ended 2025 with $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, which is expected to fund operations into the second quarter of 2027, thereby enhancing financial stability for clinical development.
- Clinical Development Progress: Prelude plans to initiate a Phase 1 trial for PRT12396 in 2026, targeting high-risk polycythemia vera and intermediate-to-high-risk myelofibrosis patients, following FDA clearance of its IND application in the first quarter of 2026, marking a significant advancement in precision oncology.
- New Drug Development Outlook: PRT13722, a highly selective KAT6A degrader for ER-positive breast cancer, is expected to file its IND in mid-2026 with a Phase 1 study commencing in the second half of 2026, showcasing the company's ongoing commitment to innovative drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRLD
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prelude Therapeutics Reports 2025 Results and Pipeline Update
- Improved Financial Performance: Prelude Therapeutics reported a net loss of $99.5 million for 2025, translating to a loss of $1.29 per share, which is an improvement from the $127.2 million loss and $1.68 per share in 2024, primarily driven by reduced research and development expenses, indicating effective cost management.
- Strong Cash Position: The company ended 2025 with $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, which is expected to fund operations into the second quarter of 2027, thereby enhancing financial stability for clinical development.
- Clinical Development Progress: Prelude plans to initiate a Phase 1 trial for PRT12396 in 2026, targeting high-risk polycythemia vera and intermediate-to-high-risk myelofibrosis patients, following FDA clearance of its IND application in the first quarter of 2026, marking a significant advancement in precision oncology.
- New Drug Development Outlook: PRT13722, a highly selective KAT6A degrader for ER-positive breast cancer, is expected to file its IND in mid-2026 with a Phase 1 study commencing in the second half of 2026, showcasing the company's ongoing commitment to innovative drug development.
See More
Prelude Therapeutics Reports FY Earnings with Revenue Surge
- Earnings Report: Prelude Therapeutics reported a FY GAAP EPS of -$1.29, missing estimates by $0.04; however, revenue surged to $12.14 million, reflecting a 73.4% year-over-year growth, indicating strong market traction.
- FDA Approval Progress: The stock climbed following FDA clearance for a cancer candidate partnered with Incyte, which not only boosts investor confidence but also paves the way for potential future revenue growth.
- Market Reaction: Despite the EPS miss, the significant revenue increase and positive FDA feedback led to a rise in Prelude's stock price, reflecting optimistic market sentiment regarding its future prospects.
- Strategic Partnership: The collaboration with Incyte not only provides Prelude with essential R&D resources but may also expedite the market entry of its cancer therapies, enhancing its position in the competitive biopharmaceutical landscape.
See More
Prelude Therapeutics Receives FDA Clearance for New Drug Application
- IND Approval: Prelude Therapeutics' PRT12396 received FDA IND clearance, with a Phase 1 study anticipated to begin in Q2 2026 for patients with polycythemia vera and myelofibrosis, marking a significant advancement in the precision oncology space and potentially offering new treatment options for patients.
- Pipeline Development: The company is advancing PRT13722, a selective KAT6A degrader, with plans to file an IND in mid-2026 and initiate a Phase 1 study in the second half of 2026, demonstrating ongoing commitment to developing innovative therapies that may enhance treatment efficacy.
- Strong Financial Position: As of December 31, 2025, Prelude reported $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, expected to fund operations into Q2 2027, reflecting effective financial management that supports ongoing R&D initiatives.
- Strategic Focus: Since its strategic shift in November 2025, Prelude has maintained a clear focus on the steady execution of its JAK2V617F inhibitor and KAT6 degrader programs, with potential key data catalysts expected in 2027 that could significantly enhance the company's market position in precision medicine.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate, significantly higher than the 10% achieved with traditional chemotherapy, which will expedite its market entry and enhance the company's position in the competitive biopharmaceutical sector.
- Significant Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study in March 2026 comparing standard care versus standard care plus pelareorep, with interim data expected by year-end, laying the groundwork for future product line expansion.
- Leadership Team Expansion: Oncolytics Biotech has recently appointed two key executives to oversee strategy and biostatistics, aiming to strengthen the company's leadership in the rapidly evolving biopharmaceutical landscape to meet the increasing demands of clinical trials.
See More
Prelude Therapeutics Receives FDA Clearance for PRT12396 Trials
- FDA Milestone: Prelude Therapeutics announced FDA clearance to dose the first patient with PRT12396 by Q2 2026, marking a significant milestone in its focus on key programs, which is expected to drive progress in blood cancer treatment.
- Trial Design: The early-stage trial will assess the safety, efficacy, and pharmacokinetic profile of PRT12396, aiming to provide new treatment options for patients with specific myeloproliferative neoplasms, thereby enhancing the company's competitive position in this niche market.
- Positive Stock Reaction: Following the FDA approval announcement, Prelude Therapeutics' shares surged 13% on Tuesday and gained an additional 2% in after-hours trading, reflecting market optimism regarding the company's future prospects and investor confidence in its drug development efforts.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around PRLD stock shifted from 'bearish' to 'bullish', with message volume increasing from 'low' to 'high', indicating a growing confidence among investors in the company's outlook, potentially driving further stock price increases.
See More
Prelude Therapeutics Reports 2025 Results and Pipeline Update
- Improved Financial Performance: Prelude Therapeutics reported a net loss of $99.5 million for 2025, translating to a loss of $1.29 per share, which is an improvement from the $127.2 million loss and $1.68 per share in 2024, primarily driven by reduced research and development expenses, indicating effective cost management.
- Strong Cash Position: The company ended 2025 with $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, which is expected to fund operations into the second quarter of 2027, thereby enhancing financial stability for clinical development.
- Clinical Development Progress: Prelude plans to initiate a Phase 1 trial for PRT12396 in 2026, targeting high-risk polycythemia vera and intermediate-to-high-risk myelofibrosis patients, following FDA clearance of its IND application in the first quarter of 2026, marking a significant advancement in precision oncology.
- New Drug Development Outlook: PRT13722, a highly selective KAT6A degrader for ER-positive breast cancer, is expected to file its IND in mid-2026 with a Phase 1 study commencing in the second half of 2026, showcasing the company's ongoing commitment to innovative drug development.
See More
Prelude Therapeutics Reports FY Earnings with Revenue Surge
- Earnings Report: Prelude Therapeutics reported a FY GAAP EPS of -$1.29, missing estimates by $0.04; however, revenue surged to $12.14 million, reflecting a 73.4% year-over-year growth, indicating strong market traction.
- FDA Approval Progress: The stock climbed following FDA clearance for a cancer candidate partnered with Incyte, which not only boosts investor confidence but also paves the way for potential future revenue growth.
- Market Reaction: Despite the EPS miss, the significant revenue increase and positive FDA feedback led to a rise in Prelude's stock price, reflecting optimistic market sentiment regarding its future prospects.
- Strategic Partnership: The collaboration with Incyte not only provides Prelude with essential R&D resources but may also expedite the market entry of its cancer therapies, enhancing its position in the competitive biopharmaceutical landscape.
See More
Prelude Therapeutics Receives FDA Clearance for New Drug Application
- IND Approval: Prelude Therapeutics' PRT12396 received FDA IND clearance, with a Phase 1 study anticipated to begin in Q2 2026 for patients with polycythemia vera and myelofibrosis, marking a significant advancement in the precision oncology space and potentially offering new treatment options for patients.
- Pipeline Development: The company is advancing PRT13722, a selective KAT6A degrader, with plans to file an IND in mid-2026 and initiate a Phase 1 study in the second half of 2026, demonstrating ongoing commitment to developing innovative therapies that may enhance treatment efficacy.
- Strong Financial Position: As of December 31, 2025, Prelude reported $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, expected to fund operations into Q2 2027, reflecting effective financial management that supports ongoing R&D initiatives.
- Strategic Focus: Since its strategic shift in November 2025, Prelude has maintained a clear focus on the steady execution of its JAK2V617F inhibitor and KAT6 degrader programs, with potential key data catalysts expected in 2027 that could significantly enhance the company's market position in precision medicine.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate, significantly higher than the 10% achieved with traditional chemotherapy, which will expedite its market entry and enhance the company's position in the competitive biopharmaceutical sector.
- Significant Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study in March 2026 comparing standard care versus standard care plus pelareorep, with interim data expected by year-end, laying the groundwork for future product line expansion.
- Leadership Team Expansion: Oncolytics Biotech has recently appointed two key executives to oversee strategy and biostatistics, aiming to strengthen the company's leadership in the rapidly evolving biopharmaceutical landscape to meet the increasing demands of clinical trials.
See More
Prelude Therapeutics Receives FDA Clearance for PRT12396 Trials
- FDA Milestone: Prelude Therapeutics announced FDA clearance to dose the first patient with PRT12396 by Q2 2026, marking a significant milestone in its focus on key programs, which is expected to drive progress in blood cancer treatment.
- Trial Design: The early-stage trial will assess the safety, efficacy, and pharmacokinetic profile of PRT12396, aiming to provide new treatment options for patients with specific myeloproliferative neoplasms, thereby enhancing the company's competitive position in this niche market.
- Positive Stock Reaction: Following the FDA approval announcement, Prelude Therapeutics' shares surged 13% on Tuesday and gained an additional 2% in after-hours trading, reflecting market optimism regarding the company's future prospects and investor confidence in its drug development efforts.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around PRLD stock shifted from 'bearish' to 'bullish', with message volume increasing from 'low' to 'high', indicating a growing confidence among investors in the company's outlook, potentially driving further stock price increases.
See More
